The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste

BACKGROUND: Prophylaxis with emicizumab provides effective bleeding protection in persons with hemophilia A (PwHA) but pressures healthcare budgets. The body weight–adjusted dosing at 7-, 14-, or 28-day intervals, according to the label, often mismatches the vial content. Entire-vial dosing resulted...

Descripción completa

Detalles Bibliográficos
Autores principales: Donners, Anouk A.M.T., van der Zwet, Konrad, Rademaker, Carin M.A., Egberts, Toine C.G., Schutgens, Roger E.G., Fischer, Kathelijn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005899/
https://www.ncbi.nlm.nih.gov/pubmed/36915864
http://dx.doi.org/10.1016/j.rpth.2023.100074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005899/
https://www.ncbi.nlm.nih.gov/pubmed/36915864
http://dx.doi.org/10.1016/j.rpth.2023.100074

Ejemplares similares